A phase I study of cabozantinib (XL184) in patients with renal cell cancer.
about
Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapyRecent advances in the management of renal cell carcinomac-Met as a Target for Personalized TherapyMet in urological cancersCabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experienceClinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selectionCabozantinib versus Everolimus in Advanced Renal-Cell CarcinomaDual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine.Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis.Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma modelsHigh Throughput Kinomic Profiling of Human Clear Cell Renal Cell Carcinoma Identifies Kinase Activity Dependent Molecular Subtypes.A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma.Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors.MET Inhibition in Clear Cell Renal Cell CarcinomaCabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.Kidney cancer and 2014: is innovation really over?Emerging tyrosine kinase inhibitors for the treatment of renal cancer.Targeting the VEGF pathway in metastatic bladder cancer.Emerging drugs for the treatment of bone metastasis.Emerging therapeutic approaches in renal cell carcinoma.Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting.Cabozantinib for the treatment of kidney cancer.A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review.Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.Cabozantinib in genitourinary malignancies.Emerging therapeutics in refractory renal cell carcinoma.Safety of available treatment options for renal cell carcinoma.Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition.Clinical efficacy of cabozantinib in two pediatric patients with recurrent renal cell carcinoma.Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib.Cabozantinib for the treatment of renal cell carcinoma.c-Met in chromophobe renal cell carcinoma.Pharmacotherapy for treating metastatic clear cell renal cell carcinoma.Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications.Targeted therapies for renal cell carcinoma.Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.Translocational renal cell carcinoma (t(6;11)(p21;q12) with transcription factor EB (TFEB) amplification and an integrated precision approach: a case reportCabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential.
P2860
Q26741450-E7520856-1937-4780-BD59-15B6AEFC8F48Q26750609-FE1BD770-CA88-4BFE-8DC7-F6B2AE7EFB76Q26775483-A4034BC4-80A4-4585-ACD9-4DC67B005F4EQ26864988-A4E11A81-EA10-41B7-8DDA-A3D73BDDE8CEQ28072166-8A082350-6B8E-449F-89EE-C4D621572EFBQ28074834-22BF549C-0006-473B-BD0E-D0587FE8E43DQ34495684-787CD3EB-4E14-436E-A540-4A4CE7D3B108Q34537725-BD626216-9939-43C6-9CEA-DDEA4B35E0A4Q34854941-2AF1C66B-922C-4E1F-AF5B-B30990EB9958Q34978329-57035403-203B-4BD9-A2EB-EE48939EC363Q35788029-9D27581C-C575-45F3-801B-D6293108F7ABQ35920803-FD2AAF8C-B9CC-4EB6-AFAD-2E9589841122Q36066539-90580E70-AE98-4674-A9FB-47A5607595F0Q36095630-5E8614EB-5323-4377-8FE2-4BFDDE69509FQ37067981-A5479EC7-B7EB-47E5-BA93-0D80E7A89325Q37672483-1AA075E8-F953-4FB1-9D9A-F26B33CB0BA5Q38465870-1D45B4E1-2A34-41D3-96CC-66AD2EABFD7DQ38485779-AA9B3323-09E0-4F70-A806-8741495C1276Q38534167-BE92D9AE-C60B-4608-B8D1-29ABE2BEDF15Q38538263-FE42D1D6-9A0E-4D25-BA45-FA4E3F24AACFQ38587958-ECBEE228-B557-49A5-AAA7-747C9D3A1E5CQ38611436-7473D1C2-D524-4A45-B755-BE7EEBD377A7Q38668871-400D8096-947A-46A9-8871-FF1F66A7A07AQ38720430-F05274B3-5839-478C-93C5-4A7780CCD9A9Q38746778-4770EE69-3611-4219-A1D8-C36253C85007Q38795560-B60B927A-E30C-4874-8328-47F22B7045CAQ38816892-15399A75-4115-48F6-8375-115E648E997DQ38824719-DE6BC005-C5B0-4391-9225-411A951986ABQ38832429-2EFBA2AA-09A4-45B1-B1B5-538AE14EFA0EQ38833200-4ACD02A0-DC11-4570-B0C1-4B36BF0717E0Q38835745-CEAC436A-4556-4247-A89A-A3A62282533EQ38979283-7B7E3289-FF22-42A8-B98E-AE0E78EBF750Q39005403-4061B41B-EC3A-4D33-8E15-80A4D74D73E4Q39051379-DBF2C915-AEE7-4F83-A8D5-9F500D4537FEQ39095194-B02A6B47-711D-47C4-86BF-B46627BDB87CQ39296942-D9B24BA8-5584-487B-B44A-8EF1B0482C33Q39425380-3736044A-E896-486E-8626-8E6A4C491D06Q41099660-C23A57B1-B8AE-4866-94B8-7515C2606C43Q42203109-8D76698D-AC56-4E0C-A178-14B028E058D3Q42257155-3728910F-FB8C-4C39-9EC2-88B22CCBE0B7
P2860
A phase I study of cabozantinib (XL184) in patients with renal cell cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
A phase I study of cabozantinib (XL184) in patients with renal cell cancer.
@en
type
label
A phase I study of cabozantinib (XL184) in patients with renal cell cancer.
@en
prefLabel
A phase I study of cabozantinib (XL184) in patients with renal cell cancer.
@en
P2093
P2860
P356
P1433
P1476
A phase I study of cabozantinib (XL184) in patients with renal cell cancer
@en
P2093
D F McDermott
J P Dutcher
K C Ferguson
S Morrissey
T K Choueiri
W G Kaelin
P2860
P304
P356
10.1093/ANNONC/MDU184
P577
2014-05-14T00:00:00Z